Yıl: 2018 Cilt: 24 Sayı: 3 Sayfa Aralığı: 90 - 95 Metin Dili: İngilizce DOI: 10.4274/vhd.2018.0006 İndeks Tarihi: 22-10-2019

Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?

Öz:
Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b andnucleoside and/or nucleotide analogues (NAs) are currently theonly two treatment approaches approved for the chronic hepatitisB (CHB). To date, few studies have compared Peg-IFN with NAsin the treatment of CHB. We aimed in this study to evaluate theeffectiveness of Peg-IFN and potent NAs (entecavir and tenofovirdisoproxil) and to compare cumulative virological and serologicalresponses in Turkish CHB patients treated between 2006 and 2016.Materials and Methods: In this observational retrospective study,we divided a total of 331 patients, who were diagnosed with CHB,into 3 groups: Peg-IFN treatment group (n=62), entecavir treatmentgroup (n=131) and tenofovir disoproxil treatment group (n=138).Results: Virologic response rate in the Peg-IFN treatment group(90%) at 12 months was higher than in the NAs treatment groups(80% for entecavir and 76% for tenofovir disoproxil) (p<0.05).Sustained virologic response (SVR) rate at 24 months was 61%in the Peg-IFN group (p<0.001). The rate of hepatitis B e antigenseroconversion was significantly higher in the Peg-IFN group (25%)than in the NAs groups (16% for entecavir, 13% for tenofovirdisoproxil). Hepatitis B surface antigen (HBsAg) seroconversion ratewas also higher in the Peg-IFN than in the NAs treatment groups(7.9% vs. 0.9% and 0%, respectively) (p<0.001). After HBsAgseroconversion, the titers of anti-HBs were retained for over sixmonths.Conclusion: Peg-IFN treatment was found to be effective with highSVR and hepatitis B e antigen and HBsAg seroconversion rates thanNAs treatment in long-term follow-up of patients with CHB. Peg-IFNappears to be the first-choice treatment approach in patients withCHB until a new era in which hepatitis B is cured.
Anahtar Kelime:

Konular: Tıbbi İnformatik Halk ve Çevre Sağlığı Mikrobiyoloji Gastroenteroloji ve Hepatoloji Hücre Biyolojisi

Pegile-İnterferon Kronik Hepatit B’de Hala Yüksek Etkili Tedavi Özelliklerine Sahip mi?

Öz:
Amaç: Pegile-interferon (Peg-IFN) alfa 2a/2b ve nükleozid ve nükleotid analogları (NA), şu anda kronik hepatit B (KHB) tedavisi için onaylanmış iki tedavi yaklaşımıdır. Bugüne kadar birkaç çalışma Peg-IFN ve NA’lar arasındaki tedavinin etkinliğini karşılaştırmıştır. Bu çalışmada, 2006-2016 yılları arasında Türk KHB hastalarında Peg-IFN ve potent NA’ların (entekavir ve tenofovir disoproksil) kümülatif virolojik ve serolojik yanıtlarını karşılaştırarak etkinliklerini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Retrospektif gözlemsel olan bu çalışmada KHB tanılı total 331 hasta (Peg-IFN tedavi grubu, n=62, entekavir tedavi grubu, n=131 ve tenofovir disoproksil tedavi grubu, n=138) değerlendirildi. Bulgular: Virolojik yanıt oranı Peg-IFN tedavi grubunda 12. ayda (%90), NA tedavi grubundan (entekavir için %80, tenofovir disoproksil için %76) daha yüksekti (p<0,05). Peg-IFN’nin 24. ayda kalıcı viral yanıt (KVY) oranı %61 idi (p<0,001). Hepatit B e antijen serokonversiyonu Peg-IFN grubunda (%25) NA grubuna (entekavir için %16, tenofovir disoproksil için %13) göre belirgin yüksekti. Hepatitis B yüzey antijeni (HBsAg) serokonversion oranı Peg-IFN grubunda NA tedavi grubuna göre daha yüksekti (%7,9 vs %0,9 ve %0) (p<0,001). HBsAg serokonversiyonundan sonra anti-HBs titreleri altı aydan fazla korundu. Sonuç: KHB hastalarının uzun sureli takibinde Peg-IFNtedavisi, NA’larına göre daha yüksek KVY ile daha yüksek HBsAg ve HBeAg serokonversiyon ile ilişkili bulundu. Peg-IFN hepatit B virüsün tedavi edildiği yeni bir döneme kadar KHB hastalarında ilk seçenek tedavi yaklaşımı olarak görünmektedir.
Anahtar Kelime:

Konular: Tıbbi İnformatik Halk ve Çevre Sağlığı Mikrobiyoloji Gastroenteroloji ve Hepatoloji Hücre Biyolojisi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
1
1
1
  • Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
  • European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
  • Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
  • LoLok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH5, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63:284-306.
  • Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA–the holygrail to hepatitis B cure. J Hepatol. 2016;64(Suppl 1):S41-S48.
  • Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 Mar. Executive Summary. Available from: https://www.ncbi. nlm.nih.gov/books/NBK305541/
  • Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelenes for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
  • Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systemic review and meta-analysis. Hepatology. 2016;63:319-333.
  • Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016;23:154-169.
  • Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C. Age- and region- specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011;11:337.
  • Mese S, Nergiz S, Tekes S, Gul K. Seroprevalence of serum HBsAg positivity and hepatitis delta virus infection among blood donors in Southeastern Turkey. Clin Ter. 2014;165:95-98.
  • Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026
  • Kemal Celen M, Tekin Koruk S, Aygen B, Dal T, Karabay O, Tosun S, Koksal I, Turgut H, Onlen Y, Balik I, Yildirim N, Sinan Dal M, Ayaz C, Tabak F. The characteristics of patients with chronic hepatitis B in Turkey. Med Glas (Zenica). 2014;11:94-98.
  • IMS Health Turkey, January 2017: www.imshealth.com/portal/site/ imshealth
  • Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
  • Korkmaz P, Usluer G, Ozgunes I, Kartal ED, Erben N, Alpat SN. Comparison of adefovir dipivoxil and pegylated interferon alpha- 2a treatment in chronic hepatitis B patients. North Clin Istanb. 2014;1:26-32.
  • Chon YE, Kim DJ, Kim SG, Kim IH, Bae SH, Hwang SG, Heo J, Jang JW, Lee BS, Kim HJ, Jun DW, Kim KM, Chung WJ, Choi MS, Jang JY, Yim HJ, Tak WY, Yoon KT, Park JY, Han KH, Suk KT, Lee HW, Jang BK, Ahn SH. An observational, multicenter, cohort study evaluating the antiviral efficacy and safety in korean patients with chronic hepatitis B receiving pegylated interferon alpha 2a (Pegasys). Medicine (Baltimore). 2016;95:e3026.
  • Yamazhan T, Kurtaran B, Pullukçu H, Yüksel E, Özkaya D, Taşbakan MI, Sipahi OR, Durusoy R, Aksu HS. Pegylated interferon in HBeAg positive and negative chronic hepatitis B patients: post treatment 1-year results of three Turkish center. J Chemother. 2014;26:339- 341.
  • Iloje UH, Yang HI, Chen CJ. Naturel history of chronic hepatitis B: what exactly has REVEAL Revealed. Liver Int. 2012;32:1333-1341.
  • Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open- label follow-up study. Lancet. 2013;381:468-475.
  • Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M, Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarete therapy in treatment-naive chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015;22:504-510.
  • Yuen MF, Ann SH, Chen DS, Chen PJ, Dusheiko GM, Hou JL, Maddrey WC, Mizokami M, Seto WK, Zoulim F, Lai CL. Chronic hepatitis B virus infection: disease revisit and management recommendations. J Clin Gastroenterol. 2016;50:286-294.
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso- Coello P, Schünemann HJ; GRADE Working Group. GRADE: An emerging concensus on rating quality of evidence and strength os recommendations. BMJ. 2008;336:924-692.
  • Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleosid analouges in patients with chronic hepatitis B. BMC Gastroenterol. 2016;16:38.
  • Xing T, Xu H, Cao L, Ye M. HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: A systematic review and network meta-analysis. PLoS ONE. 2017;12:e0169444.
  • Marcellin P, Xie Q, Paik SW, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M, Ouzan D, Foster GR, Papatheodoridis GV, Messinger D, Regep L, Bakalos G, Alshuth U, Wedemeyer H. Effectiveness of peginterferon alfa-2a therapy in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B: final results 3 years post-treatment of the prospective, global, observational S-collate study. J Hepatol 2016;64:598-599.
  • Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US-the ENUMERATE study. Aliment Pharmacol Ther. 2016;43:134-144.
  • Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, Hartmann H, Wiese M, Boeker K, Loehr HF, John C, Leuschner M, Trautwein C, Felten G, Trein A, Krause W, Ruppert S, Warger T, Hueppe D. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: A3-year prospective field practice study in Germany. Dig Dis Sci. 2016;61:3061-3071.
  • Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15:133-143.
  • Sayan M, Akhan SC ̧ Meric M. Naturally occurring amino–acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat. 2010;17:23-27.
  • Sayan M. Dogan C. Genotype/subgenotype distribition of hepatitis B virus among hemodialysis patients with Chronical Hepatitis B. Ann Hepatol. 2012:11:849-854.
APA SARIGÜL YILDIRIM F, ÜSER Ü, SAYAN M, ÖZTOPRAK ÇUVALCI N (2018). Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. , 90 - 95. 10.4274/vhd.2018.0006
Chicago SARIGÜL YILDIRIM Figen,ÜSER Ülkü,SAYAN Murat,ÖZTOPRAK ÇUVALCI NEFİSE Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. (2018): 90 - 95. 10.4274/vhd.2018.0006
MLA SARIGÜL YILDIRIM Figen,ÜSER Ülkü,SAYAN Murat,ÖZTOPRAK ÇUVALCI NEFİSE Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. , 2018, ss.90 - 95. 10.4274/vhd.2018.0006
AMA SARIGÜL YILDIRIM F,ÜSER Ü,SAYAN M,ÖZTOPRAK ÇUVALCI N Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. . 2018; 90 - 95. 10.4274/vhd.2018.0006
Vancouver SARIGÜL YILDIRIM F,ÜSER Ü,SAYAN M,ÖZTOPRAK ÇUVALCI N Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. . 2018; 90 - 95. 10.4274/vhd.2018.0006
IEEE SARIGÜL YILDIRIM F,ÜSER Ü,SAYAN M,ÖZTOPRAK ÇUVALCI N "Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?." , ss.90 - 95, 2018. 10.4274/vhd.2018.0006
ISNAD SARIGÜL YILDIRIM, Figen vd. "Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?". (2018), 90-95. https://doi.org/10.4274/vhd.2018.0006
APA SARIGÜL YILDIRIM F, ÜSER Ü, SAYAN M, ÖZTOPRAK ÇUVALCI N (2018). Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal, 24(3), 90 - 95. 10.4274/vhd.2018.0006
Chicago SARIGÜL YILDIRIM Figen,ÜSER Ülkü,SAYAN Murat,ÖZTOPRAK ÇUVALCI NEFİSE Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal 24, no.3 (2018): 90 - 95. 10.4274/vhd.2018.0006
MLA SARIGÜL YILDIRIM Figen,ÜSER Ülkü,SAYAN Murat,ÖZTOPRAK ÇUVALCI NEFİSE Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal, vol.24, no.3, 2018, ss.90 - 95. 10.4274/vhd.2018.0006
AMA SARIGÜL YILDIRIM F,ÜSER Ü,SAYAN M,ÖZTOPRAK ÇUVALCI N Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal. 2018; 24(3): 90 - 95. 10.4274/vhd.2018.0006
Vancouver SARIGÜL YILDIRIM F,ÜSER Ü,SAYAN M,ÖZTOPRAK ÇUVALCI N Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?. Viral Hepatitis Journal. 2018; 24(3): 90 - 95. 10.4274/vhd.2018.0006
IEEE SARIGÜL YILDIRIM F,ÜSER Ü,SAYAN M,ÖZTOPRAK ÇUVALCI N "Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?." Viral Hepatitis Journal, 24, ss.90 - 95, 2018. 10.4274/vhd.2018.0006
ISNAD SARIGÜL YILDIRIM, Figen vd. "Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?". Viral Hepatitis Journal 24/3 (2018), 90-95. https://doi.org/10.4274/vhd.2018.0006